Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences develops bioelectric medicine technology based on its proprietary nPulse platform, which uses nanosecond pulsed field ablation energy to deliver nanosecond electrical pulses for non-thermal cell clearing. Company news commonly centers on the nPulse Cardiac Catheter System for atrial fibrillation, clinical study disclosures, feasibility data, and presentations at electrophysiology and healthcare conferences.
Recurring updates also cover the company's work in selected applications such as surgical soft tissue ablation, investor presentations and analyst events, executive leadership changes, operating and financial results, governance matters, and capital-structure disclosures related to its common stock and financing programs.
Pulse Biosciences (NASDAQ: PLSE) will announce its financial results for Q1 2022 on May 11, 2022, after market close. A conference call will follow at 1:30 PM PT. Investors can join by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), or via a live webcast at investors.pulsebiosciences.com. The company is focused on innovative bioelectric medicine, leveraging its CellFX® System powered by Nano-Pulse Stimulation™ technology to enhance dermatologic treatments.
Pulse Biosciences (Nasdaq: PLSE) announced significant findings at the ASLMS Annual Meeting held from April 27-30, 2022, in San Diego, California. An oral presentation revealed that 12-month data for the treatment of Sebaceous Hyperplasia shows a 73% success rate in lesion clearance with good cosmetic results. A poster presentation discussed a successful case of HPV-related dermatosis treated with Nano-Pulse Stimulation (NPS). The findings highlight the clinical efficacy and safety of the CellFX® System for challenging dermatological conditions.
Pulse Biosciences, Inc. (PLSE) has announced a rights offering aimed at raising up to $15,000,000. Available to stockholders of record as of April 25, 2022, the offering will commence around May 4, 2022. Shareholders can purchase units consisting of one share of common stock and a warrant at a price based on the lesser of $3.72 or the volume-weighted average price prior to expiration on May 23, 2022. The rights offering, set to be registered with the SEC, is a strategic move to enhance liquidity and support growth initiatives.
Pulse Biosciences (Nasdaq: PLSE) announced its financial results for Q4 and full year 2021, reporting Q4 revenue of $844k and total annual revenue of $1.4 million. The company implemented leadership changes and initiated expense reduction programs to lower costs by 20%. Gross loss for Q4 was $0.4 million, with operating expenses increasing to $15 million. Full year GAAP net loss reached $63.7 million, an increase from 2020. The firm plans to enhance clinic utilization and expand the CellFX System's applications in dermatology.
Pulse Biosciences, Inc. (PLSE) will release its financial results for Q4 and full year 2021 after market close on March 31, 2022. A conference call hosted by management will follow at 1:30 PM PT. The company is known for its innovative CellFX® System using Nano-Pulse Stimulation™ technology to treat dermatologic conditions. This system aims to offer non-thermal solutions that can improve patient outcomes. Investors can access the earnings call via dial-in or webcast.
Pulse Biosciences (NASDAQ: PLSE) has appointed Kevin Danahy as its new Chief Commercial Officer (CCO). Danahy brings over 20 years of experience in medical technology, having previously driven revenue growth at Solmetex and held significant roles at Zimmer Biomet and Intuitive Surgical. His expertise is expected to enhance market penetration for the CellFX® System, which utilizes proprietary Nano-Pulse Stimulation technology to improve dermatologic outcomes. As part of his appointment, Danahy received 300,000 stock options, subject to performance-based criteria.
Pulse Biosciences, Inc. (NASDAQ: PLSE) has updated its FDA 510(k) submission to include treatment of sebaceous hyperplasia using the CellFX® System. Originally submitted in December 2021, the application received an Additional Information letter from the FDA on February 5, 2022, citing insufficient clinical evidence. The company plans to meet with the FDA in Q1 2022 to discuss the next steps, which may require more clinical data or a new submission. The CellFX System is currently approved in Europe for several dermatological conditions but faces challenges in the U.S. market.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The company will host investor meetings on February 15-16, 2022. Pulse Biosciences specializes in bioelectric medicine, focusing on health innovations to enhance patient quality of life. Their flagship product, the CellFX® System, utilizes proprietary Nano-Pulse Stimulation™ technology to effectively treat various dermatologic conditions while preserving surrounding tissues. For more details, visit pulsebiosciences.com.
Pulse Biosciences (PLSE) announced preliminary unaudited financial results for Q4 2021, estimating full-year revenue between $1.3 million to $1.4 million and Q4 revenue around $750 thousand. The company completed its first two commercial sales of the CellFX System and transitioned 17 Controlled Launch Program participants to commercial use, totaling 29 conversions. Regulatory approvals were achieved in the U.S., Europe, and Canada, setting the stage for growth in 2022.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee, scheduled for December 2, 2021. Management will engage in a fireside chat at 2:00 PM PT / 4:00 PM CT. Interested individuals can access the live and recorded webcast via the company’s website.
Pulse Biosciences specializes in bioelectric medicine, leveraging its CellFX® System and Nano-Pulse Stimulation™ technology to improve dermatologic outcomes.